search
Back to results

A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease

Primary Purpose

Pain; Bone Neoplasms; Neoplasm Metastasis

Status
Completed
Phase
Phase 4
Locations
Bulgaria
Study Type
Interventional
Intervention
Ibandronate
Sponsored by
Hoffmann-La Roche
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pain; Bone Neoplasms; Neoplasm Metastasis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Females at least 18 years of age
  • Breast cancer
  • Bone metastases

Exclusion Criteria:

  • Use of bisphosphonates within the last 3 months
  • Prior use of gallium nitrate or metastron
  • Severely impaired renal function
  • Hypocalcemia or primary hyperparathyroidism
  • Central nervous system (CNS) metastases

Sites / Locations

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Ibandronate

Arm Description

Female participants with metastatic bone disease secondary to breast cancer will receive ibandronate for a period of 25 weeks.

Outcomes

Primary Outcome Measures

Cumulative incidence of skeletal events according to Skeletal Morbidity Period Rate (SMPR)

Secondary Outcome Measures

Incidence of bone pain according to participant questionnaire
Analgesic consumption according to participant questionnaire
Change in serum pyridinoline cross-linked carboxyterminal telopeptide of collagen type I (ICTP)
Short Form 36 (SF-36) score
Incidence of adverse events (AEs)

Full Information

First Posted
September 28, 2015
Last Updated
November 1, 2016
Sponsor
Hoffmann-La Roche
search

1. Study Identification

Unique Protocol Identification Number
NCT02564107
Brief Title
A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease
Official Title
An Open Label Study of the Efficacy, Safety, and Pharmacoeconomics of Oral Ibandronate (Bondronat 50 mg) in Treatment of Metastatic Bone Disease
Study Type
Interventional

2. Study Status

Record Verification Date
November 2016
Overall Recruitment Status
Completed
Study Start Date
November 2004 (undefined)
Primary Completion Date
April 2006 (Actual)
Study Completion Date
April 2006 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hoffmann-La Roche

4. Oversight

5. Study Description

Brief Summary
This study will evaluate the efficacy, safety, and effect on quality of life of oral ibandronate (Bondronat) in participants with breast cancer and metastatic bone disease. The anticipated time on study treatment is 25 weeks, and the target sample size is 50 individuals.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain; Bone Neoplasms; Neoplasm Metastasis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
48 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Ibandronate
Arm Type
Experimental
Arm Description
Female participants with metastatic bone disease secondary to breast cancer will receive ibandronate for a period of 25 weeks.
Intervention Type
Drug
Intervention Name(s)
Ibandronate
Other Intervention Name(s)
Bondronat
Intervention Description
Participants will receive ibandronate, 50 milligrams (mg) by mouth every morning, for a period of 25 weeks.
Primary Outcome Measure Information:
Title
Cumulative incidence of skeletal events according to Skeletal Morbidity Period Rate (SMPR)
Time Frame
Up to 25 weeks
Secondary Outcome Measure Information:
Title
Incidence of bone pain according to participant questionnaire
Time Frame
Up to 25 weeks
Title
Analgesic consumption according to participant questionnaire
Time Frame
Up to 25 weeks
Title
Change in serum pyridinoline cross-linked carboxyterminal telopeptide of collagen type I (ICTP)
Time Frame
Up to 25 weeks
Title
Short Form 36 (SF-36) score
Time Frame
Up to 25 weeks
Title
Incidence of adverse events (AEs)
Time Frame
Up to approximately 7 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Females at least 18 years of age Breast cancer Bone metastases Exclusion Criteria: Use of bisphosphonates within the last 3 months Prior use of gallium nitrate or metastron Severely impaired renal function Hypocalcemia or primary hyperparathyroidism Central nervous system (CNS) metastases
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Trials
Organizational Affiliation
Hoffmann-La Roche
Official's Role
Study Chair
Facility Information:
City
Plovdiv
ZIP/Postal Code
4004
Country
Bulgaria
City
Shumen
Country
Bulgaria
City
Sofia
ZIP/Postal Code
1527
Country
Bulgaria
City
Sofia
ZIP/Postal Code
1756
Country
Bulgaria
City
Sofia
ZIP/Postal Code
1784
Country
Bulgaria
City
Stara Zagora
ZIP/Postal Code
8000
Country
Bulgaria
City
Varna
ZIP/Postal Code
9010
Country
Bulgaria
City
Veliko Tarnovo
ZIP/Postal Code
5000
Country
Bulgaria

12. IPD Sharing Statement

Learn more about this trial

A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease

We'll reach out to this number within 24 hrs